Financial Statement Release - Orion will publish its Financial Statement Release for 2025 on 12 February 2026 at approximately 12.00 noon EET [1] - The release and related presentation material will be available on the company's website after publishing [1] Webcast and Conference Call - A webcast and conference call for analysts, investors, and media representatives will be held on 12 February 2026 at 14.00 EET [2] - A link to the live webcast will be available on Orion's website, and a recording will be accessible later the same day [2] - Registration is required to join the conference call, with details provided through a specific link [2][3] Company Overview - Orion is a Nordic pharmaceutical company with over a hundred years of experience, focusing on developing, manufacturing, and marketing human and veterinary pharmaceuticals [5] - The company reported net sales of EUR 1,542 million in 2024 and employs approximately 3,700 professionals globally [5] - Orion's core therapy areas in pharmaceutical R&D include oncology and pain management, with proprietary products aimed at treating cancer, neurological diseases, and respiratory diseases [5]

Group 1 - Orion Corporation has received a notification regarding transactions made by its Chief Financial Officer, René Lindell, under the Market Abuse Regulation [1] - The transaction involved the receipt of a share-based incentive, with a volume of 4,533 shares at a unit price of 0 EUR [1] - Orion Corporation's net sales in 2024 amounted to EUR 1,542 million, and the company employed approximately 3,700 people at the end of the year [2] Group 2 - Orion Corporation is a Finnish pharmaceutical company with over a hundred years of experience in developing, manufacturing, and marketing pharmaceuticals [2] - The company has a diverse portfolio that includes proprietary and generic medicines, as well as consumer health products, focusing on oncology and pain management [2] - Orion's shares are listed on Nasdaq Helsinki, with both A and B shares available for trading [2]